Trial · NCT05199714
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Each participant's percentage of time glucose levels spent in the target range | 42 +/- 28 hours | Time in target range (3.9-10.0 mmol/L). |
| Secondary | Each participant's percentage of time of glucose levels spent between 3.9 and 7.8 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's percentage of time of glucose levels spent below 3.9 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's percentage of time of glucose levels spent below 3.0 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's percentage of time of glucose levels spent above 10.0 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's percentage of time of glucose levels spent above 13.9 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's percentage of time of glucose levels spent above 16.7 mmol/L | 42 +/- 28 hours | Glucose data will be collected from a glucose sensor and numerical glucose data will be analyzed as a function of time |
| Secondary | Each participant's mean glucose levels | 42 +/- 28 hours | |
| Secondary | Each participant's standard deviation of glucose levels | 42 +/- 28 hours | |
| Secondary | Each participant's coefficient of variance of glucose levels | 42 +/- 28 hours | |
| Secondary | Total pramlintide delivery for each participant | 28 +/- 28 hours | |
| Secondary | Total insulin delivery for each participant | 42 +/- 28 hours | |
| Secondary | Total basal insulin delivery for each participant | 42 +/- 28 hours | |
| Secondary | Total bolus insulin delivery for each participant | 42 +/- 28 hours | |
| Other | Safety Endpoints | 42 +/- 28 hours | Adverse events including gastrointestinal symptoms (nausea, vomiting, diarrhea, bloating) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05199714/registered